Biotech

0 766
Synergy Pharmaceuticals SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals is having an incredibly rough day in the market today. Unfortunately, this is following up on the declines that we saw on Friday following the company’s approval from the FDA for Trulace (Plecanatide). Below, we’ll talk about what we’re seeing from SGYP, why, and what we’ll be watching for ahead.





What We’re Seeing From SGYP

As mentioned above, Synergy Pharmaceuticals isn’t having the best of days in the market today. In fact, when the opening bell rang, the stock was already trading well in the red. From there, we’ve seen a continuation of declines, bringing it’s value further and further into the abyss. At the moment (10:57), SGYP is trading at $5.58 per share after a loss of $0.33 per share or 5.58% thus far today.

Why The Stock Is Falling

This is a bit of a tricky one. As mentioned above, SGYP hasn’t done well in the market since Friday, when it was learned that the company had achieved FDA approval for Trulace (plecanatide). The approval was for the treatment of Chronic Idiopathic Constipation. In most cases, FDA approvals cause stocks to climb. However, in this particular case, that’s not what we’ve seen.


Ultimately, while the treatment was approved, there is one thing that’s proving to be concerning for Synergy Pharmaceuticals investors. Unfortunately, while the company has achieved approval, there’s a warning that comes with the approval. Some patients may experience severe diarrhea, and that will have to be part of the warning label on the treatment. In a statement, Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research had the following to say about the SGYP approval…

No one medication works for all patients suffering from chronic gastrointestinal disorders… With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.”

What We’ll Be Watching For Ahead

First and foremost, I would like to put it out there that I believe that concerns surrounding warning labels that will be used on Trulace are well overblown. In fact, the strongest treatment on the market at the moment has the same warning label, but didn’t perform quite as well on the efficacy side as Trulace. With that said, moving forward, the CNA Finance team is eager to learn about sales reports to see how the company does with regard to commercialization. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 458
Marinus Pharmaceuticals Inc MRNS Stock News

Marinus Pharmaceuticals Inc (NASDAQ: MRNS)

Marinus Pharmaceuticals is having an overwhelmingly strong day in the market today. When the trading session kicked off, the stock was already trading well into the green. From there it seems as though it has been on a mad-dash toward the top. Below, we’ll talk about what we’re seeing from MRNS, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From MRNS

As mentioned above, Marinus Pharmaceuticals is off to an overwhelmingly strong start to the trading session today. When the opening bell rang, the stock found itself well into the green. From there, we’ve only seen a continuation of strong movement, pushing the value higher and higher. At the moment (10:02), MRNS is trading at $1.68 per share after a gain of $0.52 per share or 45.26% thus far today.

Why The Stock Is Gaining

As soon as we received the alert from Trade Ideas that MRNS was making a run for the top, the CNA Finance team started digging to see exactly what was causing the movement, In this case, it didn’t take long to uncover the story. Early this morning, the company announced positive preliminary data from the initial CDKL5 patients enrolled the company’s ongoing Phase 2 open-label study of ganaxolone as a treatment for orphan genetic disorders.


In the announcement Marinus Pharmaceuticals said that to date, 4 patients have been enrolled in this particular cohort. In the study, they have received up to 1,800 mg/kg of ganaxolone per day for an average treatment duration of five months. Of the four patients, three of them have experienced a notable reduction in seizure frequency when compared to baseline, ranging from 52% to 88%. The treatment has also shown to be generally safe and well tolerated. In a statement, Dr. Jaakko Lappalainen, Vice President of Clinical Development at MRNS had the following to offer…

We are encouraged by the results in these difficult-to-treat pediatric patients… Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration. CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MRNS. In particular, we’re interested in following the study through the process. At the moment things are looking promising, making it more exciting to watch for finalized data. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

0 532
Asterias Biotherapeutics Inc AST Stock News

Asterias Biotherapeutics Inc (NYSEMKT: AST)

On Tuesday, January 24, 2017, Asterias Biotherapeutics may be waking up its bovine friend, with potential news that can cause its resting bull to run rampant in the trading pits. On this day, AST has set a conference call to discuss new data evaluating the efficacy results six months after implantation of 10 million AST-OPC1 cells in patients with complete cervical spinal cord injuries in the ongoing SciStar clinical trial.

Now, while I don’t tend to read too much into a company setting up an unscheduled announcement to release some preliminary results, that does not mean that I do not take notice. For AST, the interim results, if positive, can be a watershed moment for the company.

What AST Investors Are Looking For On Tuesday

First off, AST is not a company that has gone completely unnoticed by investors. In fact, AST has received awards and grants from very prestigious institutions that are associated to the advancement of treatments and therapies in the spinal cord injury space. Rolling with a grant of over $14MM dollars from the California Institute For Regenerative Medicine, AST has already been able to provide some extremely encouraging data.

AST is advancing its AST-OPC1 trial, and while the phase I/IIa trial was serving to prove safety and tolerability, the results went well beyond showing the treatment to be safe, with five patients that were enrolled in the trial showing at least one motor level improvement and AST met an additional efficacy target of at least two of the patients achieving a motor skill improvement of at least two levels. On Tuesday, it is likely that AST will add additional color to what this all means, but as I wrote in a prior AST article, a two motor level improvement is extremely significant in improving quality of life for patients that have suffered a severe spinal cord injury.

While a one motor level improvement is certainly significant, a two motor level improvement is a huge milestone. The two level increase is correlated with significant increases in functional ability and can provide independence for patients, allowing them to care for themselves by being restored hand and arm function.

During the January 24th call, if AST demonstrates that its treatment has either maintained or increased function from these motor levels, I expect that the stock will be greeted with an enthusiastic reception.

The Market For SCI

For AST investors, strong data can make a huge difference in both how the company is valued today, and may lead to additional interest by large companies that would rather partner into the SCI space instead of trying to build out its own program.

Spinal cord injury affects an estimated 17,000 patients per year, and the lifetime cost for treatment can be in excess of $5 million dollars. That market makes the potential for AST enormous, as there are no approved therapies on the market. And, if additional supporting data is presented on Tuesday, AST may be sitting in the cat birds seat and set themselves into an enviable position to treat a significant portion of that lucrative market.

AST expects that it can treat over 9000 patients per year affected by SCI, 4000 directly and an additional 5000 through product label expansion. This market represents an over $2 billion dollar per year opportunity for AST, and this amount does not include the opportunity for label expansion or the benefit from their two additional on-going trials to treat AML and lung disease.

Expectations For Tuesday

While I won’t set my hopes to be met for my highest expectations, based on the data already published, I expect that the likelihood for consistent and positive data will continue for the trial. Therefore, while I still look forward to AST progressing into the 20 million dose cohort, which they believe will provide the optimal results, I do expect that the company has been able to reinforce prior results, increasing motor level’s in patients and having them maintain the improvement.

Investors have every right to be optimistic, but holding on to a bit of caution is prudent as well. With the stock still trading at a relative discount to the market potential, even mediocre news should not cause the stock too much negative impact.

If the news is strong, though, I expect that investors following this story will take advantage of these share price levels and accumulate on the news.

Do You Have A Question For AST?

If you have a question for AST that you’d like answered during the presentation, please send your question to CNAFinanceHelp@gmail.com and we will forward it to management to solicit an answer for you!!!

Join The Call!

Care to join the call? Fill out the form below to let us know you’re coming! We’ll give you a reminder the day before and day of the conference and make sure that you have the correct information to take part!

RSVP For The Webinar

* indicates required




Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I am long AST and may purchase additional shares within the next 72 hours.

[Image Courtesy of The Blue Diamond Gallery]

0 2168
Synergy Pharmaceuticals SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals wasn’t having the best of days in the market today. In fact, the stock started the day off in the red and continued on a slow, yet steady decline throughout the trading session, closing the day in the red. However, we’re seeing a spike in after-hours. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to SGYP ahead.





What We’re Seeing From SGYP

As mentioned above, Synergy Pharmaceuticals didn’t have what anyone would consider to be a good day in the market today. When the trading session opened, the stock was trading slightly in the red. However, after slow, yet steady downward movement all day, the declines became something worth looking at. By the close of the day, the stock was trading at $6.41 per share after a loss of $0.12 per share, or 1.84%. However, in the first minutes of after-hours trading, the stock is spiking. At the moment (4:06), SGYP is trading at $6.85 per share after a gain of $0.44 per share (6.86%) thus far.

Why The Stock Is Spiking

As soon as our partners at Trade Ideas sent us the alert that SGYP was spiking, the CNA Finance team started working to see why. It didn’t take long for us to dig up this story, and it’s a big one. It seems as though the gains are being caused by news surrounding one of the New Drug Applications the company has been waiting on.


Minutes ago, it was announced that the United States Food and Drug Administration has approved Synergy Pharmaceuticals’ Plecanatide for the treatment of Chronic Idiopathic Constipation, also known as CIC. This approval is a massive milestone for the company, and investors are reacting. After all, this means that the company will now be able to move Plecanatide to the commercial stage.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SGYP. Now that the company has received the approval it needs, we’re interested in seeing what the next steps are. We’ll be following the news closely and bringing it to you as it breaks!

Update – SGYP has reversed in a big way on a severe diarrhea warning associated with approval.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 1097
Perrigo PRGO Stock News

Perrigo (NYSE: PRGO)

Perrigo was having a relatively normal trading session in the market today. When the opening bell rang, the stock was in the red. However, throughout the day, we saw slow gains, bringing it to the green. Nothing about the movement was too exciting. Then, minutes ago, things changed as the stock started to spike toward the top. Below, we’ll talk about what we’re seeing from PRGO, why, and what we’ll be watching for ahead.





What We’re Seeing From PRGO

As mentioned above, Perrigo was having a relatively normal day in the market today. When the opening bell rang, the stock found itself slightly in the red. After a slow moving day of mostly upward movement, the stock made it to the green. However, nothing about the movement was worth writing home about. At the moment, that’s not the case. Minutes ago, things changed in a big way as the stock started spiking upward. Currently (11:16), PRGO is trading at $77.37 per share after a gain of $0.91 per share (1.19%) thus far today.

Why The Stock Is Spiking Upward

Our partners at Trade Ideas were the first to notify us of the spike on PRGO. As soon as they did, the CNA Finance team started digging to see exactly what was behind the movement. In this case, it didn’t take long to dig up the fake news story behind the whole thing. Ultimately, the spike is being caused by rumors that the company will be acquired, started by a fake news post.


The rumor suggests that Teva will be taking Perrigo over, and that’s an exciting idea for many. However, don’t get your hopes up. The rumor first broke on the infamous website Intereconomia. The website is known for publishing fake reports about potential takeovers and pumping a stock up. Of course, this is likely so they and their friends can profit from the movement. The rumor is not true. TEVA will not be acquiring PRGO.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching PRGO closely. In most cases with these rumors, we’re watching for validity to the claims. In this case, we’re not. We know that if Intereconomia breaks the story, it’s garbage, it’s a rumor, it’s not true! So, we’ll be watching to see the reaction in the market when the masses see that reality.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 775
Mallinckrodt PLC MNK Stock News

Mallinckrodt PLC (NYSE: MNK)

Mallinckrodt wasn’t having an incredibly exciting day in the market today. Like most stocks it seems today, it started the day off near the break even point and has traded relatively flat since. However, minutes ago, things changed in a big way. Unfortunately, the stock took a big dive. Below, we’ll talk about what we’re seeing from MNK, why, and what we’re going to be watching for ahead.





What We’re Seeing From MNK

As mentioned above, Mallinckrodt wasn’t off to the best or worst of days today in the market. When the opening bell rang, the stock found itself relatively flat, and stayed that way throughout the day. Sure, there were some times in the green and some times in the red, but nothing was worth writing home about. Nonetheless, that changed minutes ago as the stock started to fall like a brick from the Empire State Building. At the moment (2:28), MNK is trading at $44.76 per share after a loss of $4.66 per share or 9.43% thus far today.

Why The Stock Is Falling

In this particular case, our partners at Tradespoon were the first to notify us of the movement on MNK. When they did, the CNA Finance team started digging to see exactly what was causing the decline in the stock. In this case, it took no time at all. It looks like bankruptcy may be on its way for the company as the FTC takes a look.

Minutes ago, the story started breaking. The United States Federal Trade Commission is currently in the process of preparing charges against Mallinckrodt. The charges surround the company allegedly using its monopoly to jack up the price of a drug that is used to treat Lupus as well as multiple sclerosis. The price increased 2165% to its current price of about $28,000 per dose.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching MNK incredibly closely. In particular, we’re interested in learning more about the charges that will be filed and learning about the company’s defense to such charges. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Update: MNK is halted with “news pending”. We know the news… it’s not good! Of course, they haven’t made it formal yet. We’ll be following the story!

Update: There are now reports surfacing that the Obama Administration is planning on filing suit against Mallinckrodt in its final days.

Update: A rumor has emerged that MNK is already ready to announce a settlement with the FTC. The rumor is unconfirmed. The stock remains halted.

Update: It’s official, the company has made a statement saying that it has responded to the FTC with a settlement.

Update: MNK reopens higher, surprisingly in the green for the day. Currently (3:27), the stock is trading at $50.00 per share after a gain of $0.58 per share or 1.17% thus far. This is a wild ride.

 Update: An unconfirmed rumor has it that the company has made a settlement offer at $100 million. If that’s the case, that represents more than 1/3 of the $280.5 million the company has on hand. Mixed with the $6 billion in debt, things aren’t looking good.
Update: It has been confirmed. MNK has settled for a total of $100 million. Here’s the link to the FTC statement.
Update – Part of the settlement requires MNK to license rights to a generic alternative to Acthar.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 1787
Juno Therapeutics Inc JUNO Stock News

Juno Therapeutics Inc (NASDAQ: JUNO)

Juno Therapeutics was having what started off as a normal day in the market today. While the stock started the day off in the green, it quickly made its way down to the red. From there, we saw quite a bit of movement on both sides of the line as the day progressed. However, minutes ago, the stock started spiking upward in a big way. Below, we’ll talk about what we’re seeing from JUNO, why, and what we’ll be watching for ahead.





What We’re Seeing From JUNO

As mentioned above, Juno Therapeutics wasn’t having an amazing day in the market by any means. With plenty of time both above and below the breakeven point throughout the morning, the stock was having an average day in the market. However, minutes ago, that all changed as the stock started spiking upward. At the moment (11:27), JUNO is trading at $19.41 per share after a gain of $0.33 per share (1.72%) thus far today.

Why The Stock Is Spiking

As soon as the CNA Finance team received the alert from Tradespoon that JUNO was spiking, we started digging to find the reason for the movement. In this case, we were unable to find any fundamental news released by the company. However, when we started digging through social media, the reason for the spike became clear.


A rumor is circling Juno Therapeutics in the world of social media at the moment. That rumor is that the company will be taken over. However, as with most of these rumors, there is no buyer, no confirmation, and not one insinuation of validity. So, in this particular case, we’d say don’t get your hopes up. Nonetheless, it is indeed what’s causing the movement.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on JUNO. In particular, we’re interested in learning if there is any validity to this rumor. If it is true, it could return incredible value to shareholders. However, we don’t see this one as being very credible at this point. Nonetheless, we’ll watch the story closely and bring it to you as it develops!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 710
Zoetis ZTS Stock News

Zoetis Inc (NYSE: ZTS)

Zoetis is having an incredibly strong start to the trading session today. When the opening bell rang, the stock was trading well into the green. From there, it climbed a bit before correcting. Nonetheless, the spike has started again. Minutes ago, the stock made a mad dash upward. Below, we’ll talk about what we’re seeing from ZTS, why, and what we’ll be watching for ahead.





What We’re Seeing From ZTS

As mentioned above, Zoetis is off to a relatively strong start in the market today. When the opening bell rang, the stock was already trading green. Shortly thereafter, we saw a spike upward before a correction. Nonetheless, the stock has stayed in the green all day. Then, minutes ago, we started to see another spike. At the moment (10:09), ZTS is trading at $53.59 per share after a gain of $0.47 per share (0.89%) thus far today.

Why The Stock Is Climbing

When we received the alert from our partners at Trade Ideas that ZTS was making another run upward, the CNA Finance team started digging to see what was causing the movement. While we were unable to find any fundamental news that would suggest that such strong gains were coming, we did find an interesting rumor.


At the moment, there’s a rumor surfacing that the company is going to be taken over soon. According to the rumor, Boehringer is interested in dominating the global space with a strong takeover, and many believe that Zoetis is the company that’s going to be taken over. However, there has been no indication from either side that this will actually be the case.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ZTS. In particular, we’re interested in learning more about this potential takeover and whether or not it’s actually going to happen. We’ll watch the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

0 419
BIOLASE BIOL Stock News

BIOLASE Inc (NASDAQ: BIOL)

BIOLASE is having an incredibly strong start to today’s trading session. As soon as the opening bell rang, the stock started screaming to the top. From there, we’ve seen a continuation of big upward movement, driving the stock higher and higher. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to BIOL moving forward.





What We’re Seeing From BIOL

As mentioned above, BIOLASE is having an overwhelmingly strong start to the trading session today. As soon as the opening bell rang, the stock found itself in the midst of a spike. From there, we’ve seen a continuation of strong upward movement. At the moment (9:40), BIOL is trading at $1.60 per share after a gain of $0.09 per share (5.95%) thus far today.

Why The Stock Is Climbing

In this case, our partners at Tradespoon were the first to notify us of the gains on BIOL. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to uncover the story. It seems as though the gains are coming as the result of FDA news.


At the moment, there’s a ton of chatter circling 501-K approval from the FDA. It was announced that the company’s Epic Pro Laser system has indeed been approved. This is overwhelmingly positive news, as it opens the horizons quite a bit for the company’s ability to grow in the future.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching BIOL incredibly closely. In particular, we’re interested in learning more about how the company plans to move forward following the strong approval news. We’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 908
Cellceutix Corp CTIX Stock News

Cellceutix Corp (OTCMKTS: CTIX)

Cellceutix (CTIX) was the latest victim of noted short seller Mako Research, which appears to be going through their ordinary rounds of fallacious attacks, picking on the same companies in a rotary fashion, grabbing pennies when it can. But, is their style and grandeur starting to get long in the tooth losing, causing their rhetoric to lose some strength?





Granted, CTIX traded down by about ten cents on Tuesday and the volume was strong, but shrewd investors know that a good portion of that volume was orchestrated by the Mako dump crew, who coincidentally showed up today at the CTIX post and ran trading volume about 10X higher than the recent average by what appears to be a barrage of short-sale trades during the morning session.

CTIX CEO Has Some Choice Words For Mako

There is no need for me to fight the battles for CTIX, as their CEO, Leo Ehrlich, does a fine job on his own. He made sure that the market was not confused about his opinion on the newly published hit piece when he said, Mako is a pawn in an organized criminal enterprise that profits tremendously from this type of fake news that Seeking Alpha relishes publishing because it drives web traffic. There’s a reason that the courts have ruled that Seeking Alpha is not a credible news source,” He added, “We will continue to gather information on Mako and his co-conspirators.”

The Courts Opinion Of Mako And Rosen

While Mr. Ehrlich does a fine job representing, props must also be given to his legal team. Last year, the CTIX legal team sent a similar Mako attack to the recycle bin when a District Court judge published a scathing decision on its CTIX editorial, finding that the accusations had absolutely no merit whatsoever. The opinion was one of the most entertaining decisions I have read in quite a while. Not only was Mako discredited on its long-winded diatribe of inflammatory comment, so was an attorney from Rosen Law Firm, who conveniently filed a class action suit within hours of the article. This super-human legal efficiency caused the court to wonder…how could Rosen Law Firm have drafted, edited, researched, and filed such a lengthy suit in such short manner? Well, stay tuned for that part of the story, as rumor is making its way around the water cooler that Rosen Law Firm may become the poster child for unsavory sanctions by that same judge. It’s getting apparent that the court system is getting fed up with frivolous class action lawsuits that are eerily designed to act as methods of extortion rather than a means to argue legal merit. But, we shall let the judge speak to that issue, which is expected imminently.

Investing In The Real CTIX – Kevetrin

While CTIX and the short-selling players duke it out, it’s only fair that investors get some legitimate information on which to base an investment decision. CTIX is actually making strong progress in its clinical trials, advancing two compounds, Kevetrin and Purisol.

Kevetrin is demonstrating strong results in its clinical stage trial. The drug is a small molecule compound that has the potential of becoming a breakthrough cancer treatment by activating the p53 protein when targeting solid tumors. The p53 protein, which has been in focus of late, has a critical role in controlling cell mutations. Kevetrin acts to permit the normal function of the p53 pathway, allowing the body to use its natural anti-tumor defense mechanisms to ward off tumor growth. CTIX is now advancing its phase 2a trial of Kevetrin in Platinum-Resistant Ovarian Cancer. Also important to the case that CTIX is for real, Kevetrin has been granted Orphan Drug Designation by the FDA to treat Ovarian and Pancreatic cancers. And while articles may claim CTIX to be a fraud, I just can’t fathom that the FDA has been duped, whereby CTIX is producing real clinical results in an effort to disguise their real mission (stock manipulation). It’s just a bit hard to swallow.


Purisol Is Also A Potential Winner

Purisol is another strong candidate for CTIX. This compound has already demonstrated that it can successfully treat psoriasis-associated conditions. Purisol has provided strong data in two clinical trials and has shown results that even surpass the current best standard of care. On the convenience and patient compliance front, Purisol is an orally administered medication, a far more patient appreciated method of treatment than the current alternatives that require frequent doctor visits and have uncomfortable side effects and adverse events.

Purisol is a novel dermatology drug candidate that has been granted the FDA’s 505(b)2 development approach. This process streamlines the approval process by allowing the drug developer to utilize data from previously approved medications. Thus, CTIX is not put in a position whereby they will need to re-prove all of the efficacy standards of a specific ingredient in the dosage. The 505(b)2 saves considerable time and money and allows CTIX to remain multi-focused on two advancing trials.

The Next Bite Taken…CTIX Or Mako

Shareholders should stay tuned, as there is little doubt that the saga between CTIX and the land shark is far from over. Setting trader motive aside, the continued soap opera between CTIX and Mako proves that shareholders need to spend a decent amount of time vetting both the companies that they invest in, as well as sourcing the news that they read about a company.

Relying on a well written, but potentially fictitious editorial is dangerous. And those CTIX shareholders that bailed today may be sorry that they did. Mako is a declared short, and shareholders should read the articles they present as entertaining, but purposeful. Over 1.5MM shares traded in CTIX on Tuesday, over 10X its daily average. For those that think the attack was not coordinated, think again.

My point is simple. The Makos of the world will be around as long as the SEC continues to turn a blind eye in their direction. When the articles they present are fact based, they can do a shareholder well. However, when the intent is so blatantly apparent to knock a stock down, no matter the commentary, it may be best if shareholders simply left the computer and went to purchase a double mocha latte. It’s a lot easier to swallow and they won’t lose their stock during an emotional trade.

Don’t worry, though, we’ll keep you posted as to the latest developments in this ongoing battle.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1503
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...